Boot Barn Holdings, Inc. BOOT 深 沪
已收盘 01-30 16:00:00 美东时间
178.48
+3.660
+2.09%
华盛通- 最 高180.35
- 今 开173.49
- 成交量 98.59万股
- 最 低 171.69
- 昨 收 174.82
- 总市值 54.41亿
- 52周最高 210.25
- 市盈率 静 30.35
- 换手率 0.00%
- 52周最低 86.1698
- 委 比 24.22%
- 总股本 3048.36万
- 历史最高 210.25
- 量 比 1.19
- 振 幅 4.95%
- 历史最低 5.20
- 每 手 1
- 风险率 31.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Boot Barn Holdings Inc. to Announce Third Quarter Fiscal Year 2026 Results
Boot Barn Holdings Inc. to Announce Third Quarter Fiscal Year 2026 Results Boot Barn Holdings, Inc. will report its third quarter fiscal year 2026 financial results after the market close on February 4, 2026. Results will be released at http://investor.bootbarn.com. Management will host a conference
01-29 05:05
Boot Barn edges lower amid short call at Hedgeye
Boot Barn (BOOT) fell 1.8% amid a new short call from Hedgeye, which sees the potential for 75% downside. "The market is underwriting BOOT as a best-in-class unit growth story, assuming the footprint ...
01-26 23:41
美股大行评级 | 潜在上涨空间31.6%！巴克莱上调台积电目标价至450美元；第一地平线全国银行获5家机构上调目标价
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从77美元升至88美元；摩根士丹利：维持DraftKings"超配"评级，目标价从50美元升至53美元
01-20 10:26
Piper Sandler Maintains Overweight on Boot Barn Holdings, Raises Price Target to $229
Piper Sandler analyst Peter Keith maintains Boot Barn Holdings (NYSE:BOOT) with a Overweight and raises the price target from $220 to $229.
01-17 00:29
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
Applied Materials To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-12 22:26
Boot Barn Issues Strong Preliminary Q3 2026 Results
Boot Barn ( ($BOOT) ) just unveiled an announcement. Boot Barn Holdings reporte...
01-10 05:58
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
UBS Maintains Buy on Boot Barn Holdings, Raises Price Target to $265
UBS analyst Jay Sole maintains Boot Barn Holdings (NYSE:BOOT) with a Buy and raises the price target from $248 to $265.
01-09 00:10
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
